328 related articles for article (PubMed ID: 11782981)
1. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke.
Parsons MW; Barber PA; Chalk J; Darby DG; Rose S; Desmond PM; Gerraty RP; Tress BM; Wright PM; Donnan GA; Davis SM
Ann Neurol; 2002 Jan; 51(1):28-37. PubMed ID: 11782981
[TBL] [Abstract][Full Text] [Related]
2. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.
Schellinger PD; Jansen O; Fiebach JB; Heiland S; Steiner T; Schwab S; Pohlers O; Ryssel H; Sartor K; Hacke W
Stroke; 2000 Jun; 31(6):1318-28. PubMed ID: 10835451
[TBL] [Abstract][Full Text] [Related]
3. Remote ischemic perconditioning in thrombolysed stroke patients: randomized study of activating endogenous neuroprotection - design and MRI measurements.
Hougaard KD; Hjort N; Zeidler D; Sørensen L; Nørgaard A; Thomsen RB; Jonsdottir K; Mouridsen K; Hansen TM; Cho TH; Nielsen TT; Bøtker HE; Østergaard L; Andersen G
Int J Stroke; 2013 Feb; 8(2):141-6. PubMed ID: 22463392
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
Kruetzelmann A; Köhrmann M; Sobesky J; Cheng B; Rosenkranz M; Röther J; Schellinger PD; Ringleb P; Gerloff C; Fiehler J; Thomalla G
Stroke; 2011 May; 42(5):1251-4. PubMed ID: 21415399
[TBL] [Abstract][Full Text] [Related]
5. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study.
García-Bermejo P; Calleja AI; Pérez-Fernández S; Cortijo E; del Monte JM; García-Porrero M; Fe Muñoz M; Fernández-Herranz R; Arenillas JF
Cerebrovasc Dis; 2012; 34(1):31-7. PubMed ID: 22759450
[TBL] [Abstract][Full Text] [Related]
6. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
7. Stroke lesion volumes and outcome are not different in hemispheric stroke side treated with intravenous thrombolysis based on magnetic resonance imaging criteria.
Golsari A; Cheng B; Sobesky J; Schellinger PD; Fiehler J; Gerloff C; Thomalla G
Stroke; 2015 Apr; 46(4):1004-8. PubMed ID: 25700285
[TBL] [Abstract][Full Text] [Related]
8. Does Diffusion Lesion Volume Above 70 mL Preclude Favorable Outcome Despite Post-Thrombolysis Recanalization?
Tisserand M; Turc G; Charron S; Legrand L; Edjlali M; Seners P; Roca P; Lion S; Naggara O; Mas JL; Méder JF; Baron JC; Oppenheim C
Stroke; 2016 Apr; 47(4):1005-11. PubMed ID: 26979862
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours.
Röther J; Schellinger PD; Gass A; Siebler M; Villringer A; Fiebach JB; Fiehler J; Jansen O; Kucinski T; Schoder V; Szabo K; Junge-Hülsing GJ; Hennerici M; Zeumer H; Sartor K; Weiller C; Hacke W;
Stroke; 2002 Oct; 33(10):2438-45. PubMed ID: 12364735
[TBL] [Abstract][Full Text] [Related]
10. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours.
Thomalla G; Sobesky J; Köhrmann M; Fiebach JB; Fiehler J; Zaro Weber O; Kruetzelmann A; Kucinski T; Rosenkranz M; Röther J; Schellinger PD
Stroke; 2007 Feb; 38(2):313-8. PubMed ID: 17204683
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility-weighted imaging for cerebral microbleed detection in super-acute ischemic stroke patients treated with intravenous thrombolysis.
Bai Q; Zhao Z; Sui H; Xie X; Chen J; Yang J; Zhang L
Neurol Res; 2013 Jul; 35(6):586-93. PubMed ID: 23561793
[TBL] [Abstract][Full Text] [Related]
12. Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation.
Tu HT; Campbell BC; Christensen S; Desmond PM; De Silva DA; Parsons MW; Churilov L; Lansberg MG; Mlynash M; Olivot JM; Straka M; Bammer R; Albers GW; Donnan GA; Davis SM;
Int J Stroke; 2015 Jun; 10(4):534-40. PubMed ID: 23489996
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of systemic thrombolysis within 4.5 h from stroke symptom onset: a single-centre clinical and diffusion-perfusion 3T MRI study.
Floris R; Cozzolino V; Meschini A; Garaci F; Konda D; Marziali S; Sallustio F; Di Legge S; Claroni G; Fanucci E; Simonetti G; Stanzione P
Radiol Med; 2014 Oct; 119(10):767-74. PubMed ID: 24567091
[TBL] [Abstract][Full Text] [Related]
14. Can baseline magnetic resonance angiography (MRA) status become a foremost factor in selecting optimal acute stroke patients for recombinant tissue plasminogen activator (rt-PA) thrombolysis beyond 3 hours?
Ma L; Gao PY; Lin Y; Xue J; Wang XC; Wang YJ; Wang YL; Liao XL; Liu ML; Cui SM; Yu L; Tong SJ; Huang YL; Zhou YM
Neurol Res; 2009 May; 31(4):355-61. PubMed ID: 19508818
[TBL] [Abstract][Full Text] [Related]
15. Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study.
Marks MP; Olivot JM; Kemp S; Lansberg MG; Bammer R; Wechsler LR; Albers GW; Thijs V;
Radiology; 2008 Nov; 249(2):614-23. PubMed ID: 18936316
[TBL] [Abstract][Full Text] [Related]
16. Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator.
Derex L; Nighoghossian N; Hermier M; Adeleine P; Berthezène Y; Philippeau F; Honnorat J; Froment JC; Trouillas P
J Neurol Sci; 2004 Oct; 225(1-2):3-9. PubMed ID: 15465079
[TBL] [Abstract][Full Text] [Related]
17. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging.
Kidwell CS; Saver JL; Mattiello J; Starkman S; Vinuela F; Duckwiler G; Gobin YP; Jahan R; Vespa P; Kalafut M; Alger JR
Ann Neurol; 2000 Apr; 47(4):462-9. PubMed ID: 10762157
[TBL] [Abstract][Full Text] [Related]
18. Combined intravenous and intraarterial revascularization therapy using MRI perfusion/diffusion mismatch selection for acute ischemic stroke at 3-6 h after symptom onset.
Han MK; Kim SH; Ko SB; Paik NJ; Kwon OK; Lee YS; Oh CW; Kim JH; Park SH; Bae HJ
Neurocrit Care; 2008; 8(3):353-9. PubMed ID: 18340411
[TBL] [Abstract][Full Text] [Related]
19. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
[TBL] [Abstract][Full Text] [Related]
20. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
